In the era of targeted therapy, we must continue to investigate new predictive biomarkers such as BCR and BCL-2 pathway mutations to identify those CLL patients with r/r disease who should be considered for treatment in new clinical trials. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.